HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White maintains a 'Buy' rating on Inhibikase Therapeutics (NASDAQ:IKT) and raises the price target from $5 to $27.
June 30, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inhibikase Therapeutics' price target has been raised from $5 to $27 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The significant increase in the price target for Inhibikase Therapeutics by HC Wainwright & Co. indicates a strong positive outlook for the company. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100